← ProjectsP / 04Tuna-Derived Anserine PeptidesBiotech
Marine peptides for uric acid and anti-fatigue.
Patented · Specialty food
A patented (ZL202211553053.7) enzymatic process producing bluefin tuna-derived small peptides containing 2–10% anserine — a buffering dipeptide with demonstrated XOD/ADA-pathway inhibition, documented uric-acid reduction and anti-fatigue activity.
The platform targets the hyperuricemia and anti-fatigue specialty-food categories with a clinically informed natural alternative, developed via the Lan Kun Marine Biotech partnership.
Key activities
- Patented enzymatic extraction of tuna-derived peptides (ZL202211553053.7).
- Anserine concentration control (2–10%) for functional efficacy.
- Specialty-food product development for uric-acid and anti-fatigue use.
- Partnership with Lan Kun Marine Biotech.
Outcomes & targets
- Patented, repeatable marine-peptide production process.
- Natural alternative positioning in the hyperuricemia category (180M+ patients in China).
- Anti-fatigue specialty-food applications.
Industry context
Hyperuricemia and fatigue are large, under-served categories where natural, clinically informed alternatives to pharmaceutical options are in demand. A patented process and controlled active concentration provide a defensible position.
Partners
Patent · ZL202211553053.7Specialty FoodLan Kun Marine Biotech